EyePoint Inc (EYPT) News & EventsEYPTEyePoint Inc

Nasdaq Futures Rebound as Tech Stocks Recover

Nasdaq futures are rebounding as technology shares recover from last week's steep selloff and investors prepare for a busy stretch of third quarter earnings. The rebound follows the Nasdaq and S&P 500 posting their biggest weekly declines since late June, as concerns about elevated borrowing costs and the debt needed to finance AI infrastructure weighed on technology stocks. Investors are looking for evidence that massive AI investments are translating into stronger revenue and profits, with Meta Platforms, Tesla, Lam Research and Texas Instruments among the companies reporting this week.Oil prices are retreating from five-month highs, with Brent crude down about 1.3% to $108.40 a barrel and West Texas Intermediate near $101.15, following the U.S. decision to ease some sanctions on Russian oil.Beyond earnings, investors are monitoring the economic calendar for signals on the health of the housing market, consumer demand and inflation expectations. Housing-market data is due this week, followed by weekly jobless claims Thursday and preliminary manufacturing and services PMI readings and the University of Michigan's consumer sentiment survey Friday. The Federal Reserve is in its blackout period ahead of its next policy meeting, limiting opportunities for fresh guidance from policymakers.In pre-market trading, S&P 500 futures rose 0.43%, Nasdaq futures rose 1.20% and Dow futures fell 0.22%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Disc Medicineup 40% after reporting its APOLLO trial of bitopertin in erythropoietic protoporphyri met all its primary and secondary endpointsEquipmentShareup 8% after raising its FY26 revenue view citing strong customer demand and high utilization of its fleetRed Catup 7% after announcing a proposed voluntary public purchase offer to acquire all outstanding shares of Steyr Motors for EUR 39.00 per share in cashIntelup 4% after JPMorgan upgraded the stock to Neutral with an unchanged price target of $85Xanadu Quantumup 3% after receiving provisional approval for project funding worth up to $10M under DARPA's Quantum Benchmarking InitiativeUP AFTER EARNINGS -Cleveland-Cliffsup 13%GlassHouseup 2%DOWN AFTER EARNINGS -Nyxoahdown 9%Fifth Thirddown 1%LOWER -EyePointdown 81% after reporting Duravyu did not achieve the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity in its LUCIA trial

EyePoint Plans 53% Workforce Reduction to Focus on DME Development

EyePoint announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for Duravyu in diabetic macular edema, or DME. This strategic realignment follows topline readout from the Phase 3 LUCIA study of Duravyu in wet AMD, which did not meet its primary endpoint of non-inferiority, despite vision improvements, and despite meeting key secondary endpoints including reduction in treatment burden, supplement-free rates, anatomic control, and safety with redosing. The board of directors has approved a plan to reduce the company's workforce by approximately 53% of employees and to conclude the pivotal Phase 3 wet AMD trials early, without full completion of the second year of each trial. EyePoint plans to prioritize the development of Duravyu for the potential treatment of DME, which is expected to read out pivotal Phase 3 topline data in the fourth quarter of 2027. The strategic prioritization and associated operational adjustments are expected to generate estimated annualized savings of approximately $30M. The reduction is impacting approximately 53% of positions across the organization, with the substantial majority of the workforce reduction expected to occur during the fourth quarter of 2026 and to be completed during the first half of 2027. The company estimates it will incur aggregate charges of approximately $9M related to employee separation benefits, including employee severance and other related expenses. "Decisions involving a reduction in our workforce are exceptionally difficult, and we extend our deepest gratitude to our departing colleagues for their dedication and meaningful contributions. While the inherent volatility of clinical development introduces profound hurdles, our core mission remains steadfast: navigating these challenges to deliver durable therapies that can truly improve the lives of patients," said Jay Duker, president and CEO of EyePoint. "The strategic prioritization enables us to focus on our next milestone, the pivotal Phase 3 readout in DME that will evaluate DURAVYU's potential to offer a durable, long-term therapeutic option that safely reduces the overall injection burden for patients. The DME program is supported by the positive Phase 2 VERONA data showing sustained visual acuity and over 70% of patients supplement-free for six months. DURAVYU also provides continuous intracellular delivery targeting pan-VEGF, PDGF, and IL-6 pathways to address both vascular and inflammatory disease drivers, which makes DURAVYU a particularly compelling potential treatment given the nature of this disease."

EyePoint Announces LUCIA Trial Results for Duravyu

EyePoint announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of Duravyu for the treatment of wet age-related macular degeneration, or wet AMD. In LUCIA, despite demonstrating visual improvement, Duravyu did not achieve the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity, or BCVA, versus on-label 2 mg aflibercept control. Duravyu achieved key secondary endpoints including a continued favorable safety profile with redosing, along with a meaningful reduction in treatment burden, durability as demonstrated by supplement-free rates, and strong anatomic control at Week 56, consistent with the first Phase 3 LUGANO clinical trial. EyePoint will complete additional analyses of the LUCIA and pooled Phase 3 datasets to further assess next steps for Duravyu as a potential treatment for wet AMD. LUCIA enrolled 475 patients and LUGANO enrolled 432 patients. Both trials randomized patients 1:1 to Duravyu 2.7 mg every 24 weeks or on-label aflibercept 2 mg every eight weeks, with supplemental aflibercept as needed according to pre-specified criteria. LUGANO also did not meet the primary endpoint in its full dataset, despite demonstrating visual improvement. In LUGANO, Duravyu also demonstrated strong and consistent performance across key secondary endpoints, including a 42% reduction in treatment burden, a favorable safety profile with redosing, durable supplement-free rates and strong anatomic control through Week 56. The Phase 2 VERONA clinical trial in DME met its primary endpoint with extended time to first supplemental injection compared to aflibercept control for both Duravyu doses. The trial also produced clinically meaningful outcomes, including a favorable safety profile with no Duravyu-related ocular or systemic serious adverse events and an early and sustained improvement in vision and anatomical control. Duravyu 2.7mg demonstrated a +7.1 letter BCVA gain and 76-micron central subfield thickness reduction at Week 24, with a supplement-free rate of 73% versus 50% for patients in the control arm. The company continues to advance the ongoing pivotal COMO and CAPRI clinical trials, with topline data expected in the fourth quarter of 2027.